Richmond Pharmacology are pleased to announce our participation in the American Heart Association’s Hypertension Scientific Sessions 2025, held in Baltimore from 4–7 September.
Representing Richmond at Hypertension 2025:
Dr Jörg Täubel, Chief Executive Officer
James Rickard, Chief Scientific Officer
Our team will be available to discuss Richmond’s expertise in:
Early-phase hypertension and cardiovascular research
First-in-human and dose-response studies
Ambulatory BP monitoring and novel endpoints
Regulatory strategy and global trial delivery
Targeted recruitment and patient-centric design
If you’re attending Hypertension 2025 and seeking a partner in hypertension clinical development, we welcome meeting requests at: info@richmondpharmacology.com
Richmond Pharmacology Appoints Adam Hurd as Operations Director
August 17, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Adam Hurd as Operations Director
Richmond Pharmacology is excited to join the AASLD Emerging Topic Conference: Unified Frontiers in Liver Disease in Denver, USA, on 05– 09 November 2026.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
